XXXX for treatment-resistant @entity161 : results of a multicenter, randomized, double-blind, comparison study versus @entity21886 .

@entity1 @entity21886 @entity161 @entity1037 @entity1770 @entity1090
OBJECTIVE: Treatment-resistant @entity161 poses a major therapeutic challenge. This multicenter, double-blind, randomized study compared the efficacy and safety of @entity1770 and @entity21886 in treatment-resistant @entity1 with @entity161 . METHOD: @entity161 @entity1 (DSM-IV diagnosis) with a history of antipsychotic resistance underwent 4 to 6 weeks of open-label treatment with @entity1037 or @entity1090 to confirm treatment resistance. Only @entity1 who completed this open-label period and failed to respond (< 20% improvement in Positive and Negative Syndrome Scale [PANSS] total score or a Clinical Global Impressions-Severity of Illness score >or= 4) entered the 6-week, double-blind treatment phase. In all, 300 @entity1 with confirmed treatment resistance were randomly assigned to @entity1770 (15-30 mg/day) or @entity21886 (8-64 mg/day). The primary outcome measure was change in PANSS score from baseline. The study was conducted between August 30, 2000, and March 18, 2002. RESULTS: Both @entity1770 and @entity21886 treatment were associated with clinically relevant improvements in PANSS total scores from baseline. After 6 weeks, 27% of @entity1770 -treated @entity1 and 25% of @entity21886 -treated @entity1 were responders (>or= 30% decrease in PANSS total score or a Clinical Global Impressions-Improvement score of 1 or 2). @entity21886 -treated @entity1 had a higher incidence of extrapyramidal symptom-related adverse events, mean increases (i.e., worsening) in extrapyramidal symptom rating scale scores, and a higher rate of elevated prolactin levels than @entity1770 (57.7% vs. 4.4%, p < .001). Improvements in quality of life considered to be clinically relevant (>or= 20% improvement in Quality of Life Scale score) occurred in 36% of the @entity1770 -treated @entity1 and in 21% of those treated with @entity21886 (p = .052). CONCLUSIONS: @entity1770 and @entity21886 , at the doses used here, can improve the symptoms of @entity161 in treatment-resistant @entity1 who have failed to respond to @entity1037 or @entity1090 .
